Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia
This article was originally published in The Pink Sheet Daily
Executive SummaryPhase III trials for the GABA-A receptor antagonist do not support further development, the firms state.
You may also be interested in...
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.